Most Recent Articles by Shannon Aymes, MD
Rectal diazepam is currently the only FDA-approved treatment for pediatric status epilepticus.
The migraines were not likely associated with acute altitude syndrome, as the participants were conditioned to living in the low-oxygen environment.
While several studies have demonstrated efficacy in refractory epilepsy, it is still not clear how cannabidiol may have an impact on current epilepsy treatments.
There are a limited number of prediction models that identify patients at risk of major bleeding after stroke or TIA.
Most prescriptions for long-term opioid therapy were written by internal or family medicine physicians.
More Articles by Shannon Aymes, MD
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Prochlorperazine More Effective Than Ketamine for Headache Relief in the Emergency Department
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Intranasal Sumatriptan More Effectively Reduces Migraine-Associated Nausea
- Neuropsychiatric Conditions Common in Relatives of Patients With Amyotrophic Lateral Sclerosis
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- NBT System Gets FDA Clearance for Depression Treatment
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- FDA Approves Myasthenia Gravis Treatment
- Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug
- Nusinersen Improves Motor Function, Survival in Infants With Spinal Muscular Atrophy
- Noninvasive Brain Stimulation System Approved for Depression
- Hypertension Guidelines Updated by AHA/ACA
- Bone Mineral Density Associated With Intracranial Aneurysm Presence, Size